SILVER SPRING, Md., June 30, 2026
The U.S. Food and Drug Administration (FDA) has approved Tregzi, the first regulatory T-cell (Treg) immunotherapy designed to improve chronic graft-versus-host disease (GVHD)-free survival in adult patients with high-risk blood cancers undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Developed by Orca Biosystems, Tregzi introduces a groundbreaking cellular therapy that utilizes donor-derived immune cells to help rebuild the patient’s immune system while significantly reducing the risk of chronic GVHD, one of the most serious and life-threatening complications following stem cell transplantation. The approval represents a major advancement in cell therapy and hematologic oncology, providing clinicians with an innovative strategy that not only supports successful transplantation but also improves long-term quality of life for patients. The FDA’s decision follows compelling evidence from a randomized Phase 3 clinical trial demonstrating substantial improvements in chronic GVHD-free survival compared with conventional stem cell transplantation, reinforcing the growing role of advanced immune cell therapies in modern cancer care.
Novel Treg Cell Therapy Reduces Chronic GVHD After Transplantation
Tregzi is a donor-derived cellular immunotherapy composed of three carefully purified immune cell populations, including hematopoietic stem and progenitor cells (HSPCs), regulatory T cells (Treg cells), and conventional T cells (Tcon cells), collected from an 8/8 HLA-matched donor. Unlike conventional transplantation approaches, the therapy is specifically designed to promote immune reconstitution while minimizing the immune-mediated damage responsible for chronic graft-versus-host disease. Treg cells play a central role in regulating immune responses and maintaining immune tolerance, allowing donor immune cells to attack residual cancer cells while reducing harmful attacks against healthy tissues.
Patients receive Tregzi after undergoing conditioning chemotherapy prior to stem cell transplantation, providing a more balanced and controlled restoration of immune function during recovery. The approval introduces the first FDA-authorized therapy using regulatory T cells specifically to reduce chronic GVHD risk, marking an important milestone in the evolution of precision cellular immunotherapy.
Phase 3 Trial Demonstrates Significant Clinical Benefit
Advertisement
The FDA approval was supported by results from the PRECISION-T Phase 3 clinical trial, which enrolled 187 adult patients with acute leukemia, myelodysplastic syndrome, and other high-risk blood cancers undergoing allogeneic stem cell transplantation. Participants were randomly assigned to receive either Tregzi or a standard stem cell transplant, with the primary endpoint measuring chronic GVHD-free survival over a two-year period. Clinical outcomes strongly favored the investigational therapy, with 78% of patients receiving Tregzi remaining free of moderate or severe chronic GVHD at one year, compared with only 38.4% of patients receiving standard transplantation.
After adjusting for competing mortality risk, only 12.6% of Tregzi-treated patients developed serious chronic GVHD within one year compared with 44% of patients receiving conventional treatment. The therapy also demonstrated a favorable safety profile, with adverse events largely consistent with standard transplantation, primarily involving infections. Importantly, investigators reported no severe infusion reactions and no graft failures during the clinical study, supporting the therapy’s overall safety and clinical effectiveness.
FDA Approval Advances the Future of Cellular Immunotherapy
The approval of Tregzi represents a significant milestone in the rapidly expanding field of cell-based regenerative medicine and underscores the FDA’s commitment to accelerating innovative therapies through programs such as Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) Designation, both of which were granted to the product during development. Chronic graft-versus-host disease has long remained one of the greatest barriers to successful stem cell transplantation despite advances in cancer treatment, often limiting long-term survival and quality of life.
By introducing a novel immune regulatory approach capable of preventing severe GVHD while preserving anti-cancer activity, Tregzi has the potential to redefine transplantation outcomes for patients with aggressive hematologic malignancies. The approval further establishes Orca Biosystems as a leader in precision cellular therapies and highlights the growing impact of next-generation immunotherapies in improving survival for patients battling complex blood cancers.
Source: FDA press release
